Payment overview · 2025
General Payments
$1,584.49
97 reported records · 19 companies
Healthcare provider profile · identity verified
John Bauer, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CAPE GIRARDEAU, MO · NPI 1164474763
Verified facts
What the public records show
CMS Open Payments records show John Bauer, MD received $1,584.49 in general payments during 2025 across 97 reported records.
ABBVIE INC. accounted for 38.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Gemtesa, Jardiance, Mounjaro, Ozempic, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 281 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 252 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 208 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 281 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 269 claims for Ozempic by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $601.51 | 38.0% | 36 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $155.04 | 9.8% | 10 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $145.69 | 9.2% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $139.36 | 8.8% | 13 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $79.65 | 5.0% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $74.90 | 4.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.72 | 4.0% | 4 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $54.53 | 3.4% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $37.58 | 2.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $36.10 | 2.3% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $33.62 | 2.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $30.09 | 1.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.78 | 1.8% | 2 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $23.73 | 1.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.38 | 1.4% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $15.98 | 1.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $15.14 | 1.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.94 | 0.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.75 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,584.49 | 97 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $493.97 | 29 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $155.04 | 10 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $145.69 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $139.36 | 13 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $79.65 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $74.90 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $67.45 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $62.72 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $59.50 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $48.04 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $47.24 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $37.58 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $36.10 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $34.42 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $33.62 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $30.09 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $28.78 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $28.78 | 2 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $23.73 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.38 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 208 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 252 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 281 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 160 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 269 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
153 | 36 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
85 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
217 | 42 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
281 | 58 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
252 | 50 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
208 | 206 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
85 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
281 | 58 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
160 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
269 | 43 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1382 | 299 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1176 | 286 |
| Amlodipine Besylate | Amlodipine Besylate | 1083 | 263 |
| Lisinopril | Lisinopril | 842 | 213 |
| Pantoprazole Sodium | Pantoprazole Sodium | 813 | 185 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 739 | 192 |
| Hydrochlorothiazide | Hydrochlorothiazide | 737 | 177 |
| Losartan Potassium | Losartan Potassium | 700 | 151 |
| Metformin Hcl | Metformin Hcl | 611 | 156 |
| Gabapentin | Gabapentin | 554 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 545 | 131 |
| Omeprazole | Omeprazole | 506 | 111 |
| Potassium Chloride | Potassium Chloride | 425 | 103 |
| Pravastatin Sodium | Pravastatin Sodium | 393 | 97 |
| Furosemide | Furosemide | 387 | 97 |
| Tamsulosin Hcl | Tamsulosin Hcl | 379 | 102 |
| Meloxicam | Meloxicam | 374 | 93 |
| Trazodone Hcl | Trazodone Hcl | 360 | 79 |
| Valsartan | Valsartan | 349 | 91 |
| Sertraline Hcl | Sertraline Hcl | 346 | 80 |
| Alendronate Sodium | Alendronate Sodium | 321 | 79 |
| Duloxetine Hcl | Duloxetine Hcl | 316 | 74 |
| Simvastatin | Simvastatin | 313 | 79 |
| Montelukast Sodium | Montelukast Sodium | 289 | 67 |
| Alprazolam | Alprazolam | 283 | 54 |
| Jardiance | Empagliflozin | 281 | 58 |
| Ozempic | Semaglutide | 269 | 43 |
| Ezetimibe | Ezetimibe | 265 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 263 | 64 |
| Eliquis | Apixaban | 252 | 50 |
| Tramadol Hcl | Tramadol Hcl | 241 | 55 |
| Glimepiride | Glimepiride | 232 | 64 |
| Carvedilol | Carvedilol | 218 | 51 |
| Farxiga | Dapagliflozin Propanediol | 217 | 42 |
| Citalopram Hbr | Citalopram Hydrobromide | 215 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 214 | 48 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 208 | 206 |
| Allopurinol | Allopurinol | 203 | 47 |
| Lorazepam | Lorazepam | 198 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 193 | 51 |
| Hydralazine Hcl | Hydralazine Hcl | 183 | 49 |
| Famotidine | Famotidine | 180 | 43 |
| Memantine Hcl | Memantine Hcl | 180 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 177 | 42 |
| Mounjaro | Tirzepatide | 160 | 32 |
| Donepezil Hcl | Donepezil Hcl | 155 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 154 | 35 |
| Synthroid | Levothyroxine Sodium | 153 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 151 | 46 |
| Atenolol | Atenolol | 150 | 39 |
| Xarelto | Rivaroxaban | 149 | 25 |
| Aripiprazole | Aripiprazole | 146 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 146 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 38 |
| Bupropion Xl | Bupropion Hcl | 132 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 131 | 35 |
| Metformin Hcl Er | Metformin Hcl | 131 | 37 |
| Fenofibrate | Fenofibrate | 130 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 121 | 27 |
| Spironolactone | Spironolactone | 119 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 117 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 116 | 30 |
| Warfarin Sodium | Warfarin Sodium | 99 | 16 |
| Finasteride | Finasteride | 98 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 97 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 96 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 93 | 26 |
| Pregabalin | Pregabalin | 92 | 21 |
| Lovastatin | Lovastatin | 90 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 88 | 26 |
| Januvia | Sitagliptin Phosphate | 87 | 16 |
| Myrbetriq | Mirabegron | 85 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 85 | 19 |
| Prednisone | Prednisone | 82 | 59 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 81 | 33 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 81 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 78 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 75 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 72 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 70 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 70 | 18 |
| Ramipril | Ramipril | 69 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 68 | suppressed |
| Chlorthalidone | Chlorthalidone | 67 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 64 | 14 |
| Methylprednisolone | Methylprednisolone | 64 | 60 |
| Meclizine Hcl | Meclizine Hcl | 63 | 23 |
| Clonidine Hcl | Clonidine Hcl | 60 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 60 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 60 | 17 |
| Glipizide Er | Glipizide | 58 | 22 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 57 | 15 |
| Propranolol Hcl | Propranolol Hcl | 57 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 55 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 55 | 12 |
| Tradjenta | Linagliptin | 55 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 54 | suppressed |
| Torsemide | Torsemide | 54 | 11 |
| Carbamazepine | Carbamazepine | 53 | 14 |
| Folic Acid | Folic Acid | 53 | 16 |
| Verapamil Er | Verapamil Hcl | 53 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 51 | 13 |
| Raloxifene Hcl | Raloxifene Hcl | 51 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 49 | 11 |
| Glipizide | Glipizide | 49 | 15 |
| Nifedipine Er | Nifedipine | 48 | 15 |
| Celecoxib | Celecoxib | 46 | 16 |
| Trulicity | Dulaglutide | 46 | suppressed |
| Clonazepam | Clonazepam | 45 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | suppressed |
| Irbesartan | Irbesartan | 44 | 12 |
| Incruse Ellipta | Umeclidinium Bromide | 42 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 42 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 41 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 35 |
| Liothyronine Sodium | Liothyronine Sodium | 39 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 39 | suppressed |
| Entresto | Sacubitril/Valsartan | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 20 |
| Topiramate | Topiramate | 36 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 35 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 34 | suppressed |
| Ketoconazole | Ketoconazole | 33 | 19 |
| Sucralfate | Sucralfate | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Digoxin | Digoxin | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 21 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 24 | 23 |
| Livalo | Pitavastatin Calcium | 24 | suppressed |
| Premarin | Estrogens, Conjugated | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Febuxostat | Febuxostat | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Gemtesa | Vibegron | 22 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 20 |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 17 |
| Armour Thyroid | Thyroid,pork | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 15 |
| Jentadueto | Linagliptin/Metformin Hcl | 18 | suppressed |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Minoxidil | Minoxidil | 18 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 14 |
| Nystatin | Nystatin | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Captopril | Captopril | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 16 |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Xifaxan | Rifaximin | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Glyburide | Glyburide | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 13 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Edarbi | Azilsartan Medoxomil | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Norethindrone Acetate | Norethindrone Acetate | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Budesonide Dr | Budesonide | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,584.49 · 97 records | ABBVIE INC. | AREXVY, BREZTRI, Dexcom G6 Transmitter, ELIQUIS, GEMTESA, JARDIANCE, LEQVIO, Leqembi, MOUNJARO, NEXPLANON, Ohtuvayre, Ozempic, QULIPTA, REXULTI, Rybelsus, SHINGRIX, Tymlos, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, XIFAXAN, YUPELRI, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error